Short Interest in MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) Decreases By 25.4%

MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) was the target of a large decrease in short interest in the month of March. As of March 15th, there was short interest totalling 708,700 shares, a decrease of 25.4% from the February 28th total of 950,600 shares. Currently, 3.3% of the company’s shares are short sold. Based on an average daily volume of 278,000 shares, the days-to-cover ratio is presently 2.5 days.

Institutional Trading of MAIA Biotechnology

A number of large investors have recently bought and sold shares of MAIA. XTX Topco Ltd acquired a new position in shares of MAIA Biotechnology in the 3rd quarter valued at about $31,000. Jane Street Group LLC bought a new stake in MAIA Biotechnology in the fourth quarter worth approximately $77,000. Finally, Geode Capital Management LLC lifted its stake in MAIA Biotechnology by 22.9% in the third quarter. Geode Capital Management LLC now owns 192,563 shares of the company’s stock valued at $541,000 after buying an additional 35,821 shares during the period. 5.65% of the stock is currently owned by institutional investors and hedge funds.

MAIA Biotechnology Stock Performance

Shares of NYSEAMERICAN MAIA traded down $0.09 during midday trading on Monday, reaching $1.53. The stock had a trading volume of 96,659 shares, compared to its average volume of 238,164. MAIA Biotechnology has a twelve month low of $1.46 and a twelve month high of $5.99. The firm has a 50 day simple moving average of $1.83. The company has a market cap of $40.02 million, a price-to-earnings ratio of -1.11 and a beta of 0.20.

About MAIA Biotechnology

MAIA Biotechnology, Inc, a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer. The company's lead product candidate is THIO, a telomere-targeting agent that is in Phase II clinical study to evaluate its activity in patients with non-small cell lung cancer.